GlassScriptPhysician profile
Susan Berger
NPI 1205879111
$11,522.45
in general payments reported to CMS, 2019-2025
35 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,434 · 2020: $563 · 2021: $694 · 2022: $1,157 · 2023: $1,980 · 2024: $2,066 · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,567 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,567.35 |
| Education | $106.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,547.02 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $1,143.70 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Janssen Biotech, INC. | $1,113.28 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,019.22 | 2019-2025 | |
| Lilly USA, LLC | $897.56 | 2019-2025 | Taltz |
| Pfizer INC. | $633.78 | 2019-2025 | |
| Ucb, INC. | $626.04 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $534.03 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $431.75 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $428.34 | 2019-2023 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.33 | 2019-2025 | Spevigo |
| Ani Pharmaceuticals, INC. | $355.26 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Sobi, INC | $314.09 | 2019-2025 | |
| Progentec Diagnostics, INC. | $307.89 | 2023 | |
| Glaxosmithkline, LLC. | $233.72 | 2019-2025 | Benlysta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $222.40 | 2019 | |
| Radius Health, INC. | $192.35 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $150.94 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $117.48 | 2020-2025 | Acthar |
| Fresenius Kabi USA, LLC | $114.99 | 2024-2025 | Idacio |
| Genzyme Corporation | $107.34 | 2021-2025 | |
| Invivyd INC | $91.75 | 2024-2025 | Pemgarda |
| Janssen Scientific Affairs, LLC | $88.69 | 2019 | |
| Sandoz INC. | $76.23 | 2023-2024 | Hyrimoz |
| Hikma Pharmaceuticals USA | $73.31 | 2019 | |
| Celgene Corporation | $63.79 | 2019 | |
| Genentech USA, INC. | $51.64 | 2019-2025 | Actemra |
| US Oncology Corporate, INC. | $44.55 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $34.90 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $26.47 | 2022 | |
| Biocon Biologics INC | $24.76 | 2023 | Hulio |
| Alexion Pharmaceuticals, INC. | $20.50 | 2023 | Strensiq |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $14.26 | 2020 | |
| Vertical Pharmaceuticals, LLC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.